Dynamic Methylation Clock Velocity Guides Phase‑Specific Autophagy Modulation to Optimize OSK‑Mediated Partial Reprogramming

Hypothesis

Continuous monitoring of epigenetic age reversal velocity (ΔAge/Δtime) during transient OSK expression can be used as a real‑time control signal to modulate autophagy activity, thereby aligning the cell’s rationing response with the metabolic peaks of reprogramming and improving rejuvenation outcomes while minimizing tumorigenic risk.

Mechanistic Rationale

OSK‑induced partial reprogramming imposes a transient epigenetic reset that consumes ATP and nucleotides for chromatin remodeling and histone turnover. Our “siege” model posits that autophagy is activated not to clear damage but to ration intracellular macromolecules—proteins, lipids, organelles—into reusable building blocks when biosynthesis outpaces nutrient uptake. The rate of DNA methylation demethylation, captured by clocks such as LUC or pan‑tissue clocks, directly reflects the intensity of this epigenetic remodeling and thus the instantaneous demand for recycled metabolites. When clock velocity is high, the cell is in a deep siege state and autophagy flux should be upregulated to sustain biosynthesis; when velocity plateaus or declines, the siege eases and excessive autophagy risks prematurely catabolizing essential structures, potentially triggering apoptosis or senescence.

Thus, autophagy modulation should be phase‑specific: boost autophagy (e.g., with low‑dose rapamycin or spermidine) during periods of rising clock velocity, and inhibit or basal‑level autophagy (e.g., with chloroquine or ATG5 siRNA) when velocity falls below a personalized threshold. This creates a feedback loop where the methylation clock is not just a biomarker but a therapeutic dial that tunes the rationing system to match the cell’s siege intensity.

Testable Predictions

1. In aged mice receiving inducible AAV‑OSK, real‑time measurement of LUC clock velocity will correlate inversely with intracellular free amino acid levels and positively with LC3‑II/I ratio (autophagy flux) during the first 48 h of each pulse.
2. Pharmacological enhancement of autophagy (rapamycin 0.5 mg/kg) administered only when clock velocity exceeds the 75th percentile of its baseline distribution will yield a greater reduction in epigenetic age (‑2.5 years LUC) compared with constant‑dose rapamycin, without increasing markers of apoptosis (cleaved caspase‑3) or proliferation (Ki‑67).
3. Conversely, autophagy inhibition (chloroquine 50 mg/kg) applied when clock velocity drops below the 25th percentile will preserve tissue‑specific gene expression profiles (reduced ectopic OCT4 expression) and lower incidence of hyperplasia, while constant inhibition will blunt age‑reversal benefits.
4. Combining velocity‑guided autophagy modulation with OSK will extend median lifespan beyond the 109% observed with OSK alone, and this extension will be abrogated if autophagy genes are knocked out specifically in hepatocytes, confirming the mechanistic link.

Experimental Design (Proof‑of‑Concept)

• Model: 18‑month‑old C57BL/6J mice with liver‑specific, doxycycline‑inducible AAV‑OSK.
• Monitoring: Serial tail‑vein blood draws every 12 h for cfDNA methylation sequencing; compute LUC clock velocity using a sliding‑window linear regression.
• Intervention Arms: (a) OSK only; (b) OSK + constant rapamycin; (c) OSK + velocity‑guided rapamycin (administered when velocity > 75th percentile); (d) OSK + velocity‑guided chloroquine (administered when velocity < 25th percentile); (e) OSK + autophagy‑deficient (ATG5‑LKO) controls.
• Readouts: LUC epigenetic age at weeks 4, 8, 12; hepatic LC3‑II/I, p62, ATP/AMP ratio; apoptosis (TUNEL, cleaved caspase‑3); senescence (p16^INK4a, SA‑β‑gal); tumorigenic burden (AFP, histology).
• Analysis: Mixed‑effects models to test interaction between time, intervention arm, and clock velocity on epigenetic age and functional endpoints.

If velocity‑guided autophagy modulation outperforms static dosing, it will validate the siege‑rationing framework and establish a dynamic, biomarker‑driven strategy for safe, effective epigenetic reprogramming.